South Korea · Delayed Price · Currency is KRW Aminologics Statistics
Total Valuation
Aminologics has a market cap or net worth of KRW 125.50 billion. The enterprise value is 78.69 billion.
| Market Cap | 125.50B |
| Enterprise Value | 78.69B |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aminologics has 87.83 million shares outstanding. The number of shares has decreased by -23.92% in one year.
| Current Share Class | 87.83M |
| Shares Outstanding | 87.83M |
| Shares Change (YoY) | -23.92% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 0.17% |
| Float | 59.89M |
Valuation Ratios
The trailing PE ratio is 35.73.
| PE Ratio | 35.73 |
| Forward PE | n/a |
| PS Ratio | 5.70 |
| PB Ratio | 2.24 |
| P/TBV Ratio | 2.32 |
| P/FCF Ratio | 50.31 |
| P/OCF Ratio | 49.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.27, with an EV/FCF ratio of 31.54.
| EV / Earnings | 22.34 |
| EV / Sales | 3.57 |
| EV / EBITDA | 19.27 |
| EV / EBIT | 21.89 |
| EV / FCF | 31.54 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.29.
| Current Ratio | 2.85 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 3.97 |
| Debt / FCF | 6.50 |
| Interest Coverage | 3.65 |
Financial Efficiency
Return on equity (ROE) is 6.54% and return on invested capital (ROIC) is 8.98%.
| Return on Equity (ROE) | 6.54% |
| Return on Assets (ROA) | 3.19% |
| Return on Invested Capital (ROIC) | 8.98% |
| Return on Capital Employed (ROCE) | 6.35% |
| Weighted Average Cost of Capital (WACC) | 8.12% |
| Revenue Per Employee | 550.51M |
| Profits Per Employee | 88.04M |
| Employee Count | 40 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 2.32 |
Taxes
| Income Tax | -6.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.00% in the last 52 weeks. The beta is 0.78, so Aminologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | +56.00% |
| 50-Day Moving Average | 1,515.90 |
| 200-Day Moving Average | 1,170.56 |
| Relative Strength Index (RSI) | 50.05 |
| Average Volume (20 Days) | 390,036 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aminologics had revenue of KRW 22.02 billion and earned 3.52 billion in profits. Earnings per share was 40.00.
| Revenue | 22.02B |
| Gross Profit | 9.83B |
| Operating Income | 3.59B |
| Pretax Income | 3.52B |
| Net Income | 3.52B |
| EBITDA | 4.08B |
| EBIT | 3.59B |
| Earnings Per Share (EPS) | 40.00 |
Balance Sheet
The company has 63.03 billion in cash and 16.21 billion in debt, with a net cash position of 46.82 billion or 533.07 per share.
| Cash & Cash Equivalents | 63.03B |
| Total Debt | 16.21B |
| Net Cash | 46.82B |
| Net Cash Per Share | 533.07 |
| Equity (Book Value) | 55.99B |
| Book Value Per Share | 631.45 |
| Working Capital | 51.03B |
Cash Flow
In the last 12 months, operating cash flow was 2.54 billion and capital expenditures -45.70 million, giving a free cash flow of 2.49 billion.
| Operating Cash Flow | 2.54B |
| Capital Expenditures | -45.70M |
| Depreciation & Amortization | 495.48M |
| Net Borrowing | 19.75B |
| Free Cash Flow | 2.49B |
| FCF Per Share | 28.41 |
Margins
Gross margin is 44.65%, with operating and profit margins of 16.32% and 15.99%.
| Gross Margin | 44.65% |
| Operating Margin | 16.32% |
| Pretax Margin | 15.96% |
| Profit Margin | 15.99% |
| EBITDA Margin | 18.54% |
| EBIT Margin | 16.32% |
| FCF Margin | 11.33% |
Dividends & Yields
Aminologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 23.92% |
| Shareholder Yield | 23.92% |
| Earnings Yield | 2.81% |
| FCF Yield | 1.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 23, 2009. It was a forward split with a ratio of 5.
| Last Split Date | Oct 23, 2009 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Aminologics has an Altman Z-Score of 1.79 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.79 |
| Piotroski F-Score | 4 |